author-photo

Mikiko Nakamura

Chugai Pharmaceutical Co.

11

Papers

121

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Applications of PBPK Modeling and Simulations in The Clinical Pharmacology Field: Lessons from Several Case Studies

2020 Rinsho Yakuri\/japanese Journal of Clinical Pharmacology and Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy

2019 Clinical Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (41)
Time‐to‐event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma

2018 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (2)
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent

2018
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib.

2016 Aaps Journal
Show All
- Source
- Cite
- Save
Citations (35)
Biomarker analysis of a randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous RO5137382/GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC) (NCT01507168).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Assessment of intestinal availability (FG) of substrate drugs of cytochrome p450s by analyzing changes in pharmacokinetic properties caused by drug-drug interactions.

2014 Drug Metabolism and Disposition
Show All
- Source
- Cite
- Save
Citations (26)
Gpc3-anzielendes therapeutikum für die verabreichung an einen mittels einer therapie mit dem gpc3-anzielenden therapeutikum behandelten patienten

2013
Show All
- Source
- Cite
- Save
Citations (0)